The stock of Ginkgo Bioworks Holdings Inc. (NYSE:DNA) increased by $0.11 on Monday to finish at $1.79, up 6.55 percent. The last five days have seen an average of 14,693,680 shares of common stock traded. 9 times new highs were reached in the current year, with a gain of $0.1000. The average number of shares traded over the last 20 days was 20,081,070, while the average volume over the last 50 days totaled 21,831,596.
DNA stock dropped -26.64% since last month. On 08/18/23, the company’s shares reached a one-month low of $1.5500. The stock touched a high of $3.52 on 07/19/23, after rallying from a low of $1.12 in 52 weeks. The price of DNA stock has risen by 5.92% or $0.1000 this year, reaching a new high 9 times. Still, the stock price is down -49.15% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
DNA stock investors should be aware that Ginkgo Bioworks Holdings Inc. (DNA) stock had its last reported insider trading activity 5 days ago on Aug 24. On Aug 24, Kelly Jason R sold 100,000 shares at $1.70 each. This transaction resulted in the insider making $169,800. On Aug 24, Shetty Reshma P. sold 37,650 shares at a price of US$1.70. After the transaction, the insider now owns 13,014,594 shares. 10% Owner Canton Barry had earlier sold 37,650 shares on Aug 24 for $1.70 a share. The transaction was completed for $64,043.
Valuation Metrics
Beta for the stock is 1.31. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 10.74, the price-to-book (PB) ratio of 2.29.
Financial Health
For the three months ended June 29, Ginkgo Bioworks Holdings Inc.’s quick ratio was 7.50, while its current ratio was 7.50, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 70.70% percent. Based on annual data, it had gross profit of $273.49 million and revenue of $477.71 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. DNA’s return on assets (ROA) during the last 12 months has been -53.70%. There was a -124.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -77.90%.
Earnings Surprise
According to Ginkgo Bioworks Holdings Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. It was predicted that Ginkgo Bioworks Holdings Inc.’s quarterly earnings would be -$0.09, but it ended up being -$0.08, beating the consensus by -12.50%. EBITDA was -$165.93 million for the quarter. At the end of Ginkgo Bioworks Holdings Inc.’s most recent quarter ended June 29, its liabilities totaled 788.41 million, while its total debt was $410.94 million. Equity owned by shareholders amounts to $1.98 billion.
Technical Picture
Here’s a quick look at Ginkgo Bioworks Holdings Inc.’s (DNA) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 48.88%, suggesting the stock is Neutral, with a 80.41% historical volatility rate.
The stochastic %K and %D were 25.40% and 25.04% respectively, while the average true range (ATR) was 0.1498. Based on the 14-day stochastic reading of 38.10%, the RSI (14) reading is 46.74%. On the 9-day MACD Oscillator, the stock is at 0.0322, and the 14-day reading is at -0.0250.
Analyst Ratings
Ginkgo Bioworks Holdings Inc. (NYSE: DNA) was downgraded by Goldman to a a Sell rating in its latest research report. The stock was previously rated as a a Neutral. Analysts have assigned Ginkgo Bioworks Holdings Inc. (DNA) an Overweight rating. DNA is a stock that is recommended for selling by 1 brokerage firm, while 2 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.
What is DNA’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.25 and $12.00, with a median target price of $3.00. In analyzing these forecasts, the average price target given by analysts for Ginkgo Bioworks Holdings Inc. (DNA) is $4.09.
